Trevor Anthony Mill
Corporate Officer/Principal presso COMPASS PATHWAYS PLC
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Steven John Green | M | 47 |
Silver Acquisition Co. Ltd.
 Silver Acquisition Co. Ltd. BiotechnologyHealth Technology Founded in 2014, Silver Acquisition Co. Ltd. is a biotechnology research and British experimental development company. Part of Biogen, Inc., the company is based in Maidenhead, UK. The company's focus is on developing new biotechnology products through research and experimentation.
Convergence Pharmaceuticals Holdings Ltd.
 Convergence Pharmaceuticals Holdings Ltd. Financial ConglomeratesFinance Part of Biogen, Inc., Convergence Pharmaceuticals Holdings Ltd. functions as an investment holding British company. The company is based in Maidenhead, UK.
Old Convergence Pharmaceuticals Ltd.
 Old Convergence Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2010, Old Convergence Pharmaceuticals Ltd. is a subsidiary of Biogen, Inc. that develops analgesics for the treatment of chronic pain. The company is based in Maidenhead, UK.
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | 10 anni |
| Mary-Rose Hughes | F | - | 4 anni | |
| Douglas Lankler | M | 58 | 25 anni | |
| David Norton | M | 72 | 6 anni | |
| Thomas Lönngren | M | 73 | 5 anni | |
| Nicole Murphy | F | - | 9 anni | |
| Kabir Kumar Nath | M | 59 | 2 anni | |
| Michael Hencke | M | - | 12 anni | |
| Jesus Mantas | M | 55 | 5 anni | |
| Sally Susman | F | 62 | 17 anni | |
| David Witty | M | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Annalisa Jenkins | M | 58 | 6 anni | |
| William Hawkins | M | 70 | 5 anni | |
| Robert McQuade | M | 67 | 4 anni | |
| Wayne Riley | M | 64 | 3 anni | |
| Linda McGoldrick | M | 69 | 4 anni | |
| Suzanne Johnson | F | 66 | 17 anni | |
| Joanne Palmer | F | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Ged Giblin | M | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Greg Ryslik | M | - | - | |
| Barbara Dalton | M | 69 | 17 anni | |
| Annaliesa Anderson | M | - | 17 anni | |
| Ben Harber | M | - | - | |
| Markus Green | M | - | 18 anni | |
| Gary Gilmour | M | - | - | |
| Matthew Owens | M | 46 | 2 anni | |
| Mike McDermott | M | 58 | 21 anni | |
| Guy Goodwin | M | 76 | 3 anni | |
| Anne Benedict | F | - | 3 anni | |
| Lorraine Deborah Barr | F | 58 |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | - |
| Stephen D. Schultz | M | - | 4 anni | |
| Denis Patrick | M | - | 14 anni | |
| Natacha Gassenbach | F | - | 6 anni | |
| Thomas Insel | M | 72 | - | |
| Christopher Williams | M | - | - | |
| Neil Raymond Sisak | M | 53 |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | - |
| Daphne Karydas | F | 49 | 1 anni | |
| Jake Elkins | M | - | 7 anni | |
| Suneet Varma | M | 55 | 23 anni | |
| Robin Kramer | F | 58 | 6 anni | |
| Valerie Morisset | M | 55 |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Ginger Gregory | M | 56 | 7 anni | |
| Mikael Dolsten | M | 65 | 15 anni | |
| Johanna Friedl-Naderer | F | 56 |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 63 | 63.00% |
| Regno Unito | 38 | 38.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Trevor Anthony Mill
- Contatti personali